SPRY News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

SP

Mkt Cap

$404.8M

Volume

2.07M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRYA securities class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly stated coverage would begin July 1, 2026, while concealing material adverse facts about the actual timeline, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.GlobeNewswire Inc. · Oct 2, 2026

ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff RoleA class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product (neffy) with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to adequately disclose risks that the deadline might not be met, potentially impacting summer and back-to-school sales.GlobeNewswire Inc. · Oct 2, 2026

ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRYA securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about expected July 1, 2026 coverage, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.GlobeNewswire Inc. · Sep 29, 2026

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Tigo Energy, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TYGORosen Law Firm has filed securities class action lawsuits against Tigo Energy, Inc., AST SpaceMobile, Inc., and ARS Pharmaceuticals, Inc. The Tigo lawsuit alleges the company made materially false statements regarding revenue projections based on an EG4 partnership that would not materially contribute revenue until Q4 2026 at the earliest. Investors who purchased securities during the class periods may be eligible for compensation. Lead plaintiff deadlines vary by case.GlobeNewswire Inc. · Sep 29, 2026

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawSchall, Brown & Schwartz LLP announced a securities fraud class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for making false and misleading statements regarding timeline issues related to CVS Caremark's addition of neffy to its formulary. The class period spans March 9, 2026 to June 24, 2026, with an October 5, 2026 deadline for investors to participate. Shareholders who suffered losses are encouraged to contact the firm regarding lead plaintiff appointments.GlobeNewswire Inc. · Sep 24, 2026

מועד אחרון לתביעה ייצוגית נגד DATAVAULT AI: רוזן, יועץ למשקיעים מהימן, קורא למשקיעי Datavault AI Inc. לשכור ייצוג משפטי לקראת מועד חשוב ב- 5 באוקטובר בתביעה ייצוגית בניירות הערך – DVLTRosen Law Firm announces class action securities lawsuits against Datavault AI Inc. (DVLT) and ARS Pharmaceuticals Inc. (SPRY), with October 5, 2026 deadline for investors to join. The Datavault AI lawsuit alleges false statements regarding business partnerships, platform activity, and undisclosed connections to a convicted felon. Investors who purchased securities during specified periods may be eligible for compensation.GlobeNewswire Inc. · Sep 23, 2026

מועד אחרון לתביעה ייצוגית נגד ARS PHARMACEUTICALS: רוזן, יועץ למשקיעים מהימן, קורא למשקיעי ARS Pharmaceuticals, Inc. לשכור ייצוג משפטי לקראת מועד אחרון חשוב בתביעה הייצוגית בניירות הערך – SPRYRosen Law Firm announces class action securities lawsuits against ARS Pharmaceuticals (SPRY) and Datavault AI (DVLT), with October 5, 2026 deadline for investors to join. ARS Pharmaceuticals is accused of providing misleading statements regarding insurance coverage expansion timeline for its epinephrine spray product neffy through CVS Caremark, allegedly causing investors to purchase shares at artificially inflated prices.GlobeNewswire Inc. · Sep 23, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRYPomerantz Law Firm has filed a class action lawsuit against ARS Pharmaceuticals (NASDAQ: SPRY) alleging securities fraud. The lawsuit was triggered after ARS announced on June 24, 2026, that it failed to secure expanded insurance coverage for its epinephrine nasal spray product 'neffy' through CVS Caremark by the July 1 deadline. The announcement caused ARS's stock to plummet 23.91% to $8.02 per share on June 25, 2026. Investors have until October 5, 2026, to request appointment as Lead Plaintiff.GlobeNewswire Inc. · Sep 22, 2026

ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRYA securities class action lawsuit has been filed against ARS Pharmaceuticals (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about a July 1, 2026 coverage start date, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.GlobeNewswire Inc. · Sep 22, 2026

AARD IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARDRosen Law Firm is reminding investors in Aardvark Therapeutics (AARD), UWM Holdings (UWMC), and ARS Pharmaceuticals (SPRY) of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made materially false statements and failed to disclose material adverse facts about their businesses, with Aardvark specifically accused of overstating the safety and commercial prospects of its ARD-101 drug candidate.GlobeNewswire Inc. · Sep 19, 2026

SP

SPRYARS Pharmaceuticals, Inc. Common Stock

SPRY

Pay with—

Available Balance0.00

Your PositionYou don't own any SPRY yet.

Related Tickers

Earnings